Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging.
Giordano S
Sci Rep. 2016 Dec 21;6:39284. doi: 10.1038/srep39284
Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M
Ann Oncol. 2016 Jan 17;27(4):625-34. doi: 10.1093/annonc/mdw007
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
Vázquez R
Int J Cancer. 2016 Sep 19;140(1):197-207. doi: 10.1002/ijc.30412
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
Belgiovine C
Br J Cancer. 2017 Jul 6;117(5):628-638. doi: 10.1038/bjc.2017.205
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
Colombo N
Br J Cancer. 2019 Sep 20;121(9):744-750. doi: 10.1038/s41416-019-0584-5
Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
Frapolli R
Clin Cancer Res. 2019 Sep 3;25(24):7565-7575. doi: 10.1158/1078-0432.CCR-19-0976
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
Bello E
Br J Cancer. 2019 Aug 14;121(6):464-473. doi: 10.1038/s41416-019-0550-2
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
Cortinovis D
Clin Lung Cancer. 2020 Jul 3;22(4):361-370.e3. doi: 10.1016/j.cllc.2020.06.028
Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis.
Paracchini L
JAMA Netw Open. 2020 Jul 1;3(7):e207566. doi: 10.1001/jamanetworkopen.2020.7566
Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer.
Paracchini L
Clin Cancer Res. 2020 Dec 15;27(9):2549-2559. doi: 10.1158/1078-0432.CCR-20-3345